Magazine Article | February 7, 2018

Companies To Watch: Zavante

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Challenging drug resistance with a retooled antibiotic and a broad mechanism of action.

Zavante has completed a pivotal Phase 2/3 trial of its lead broad-spectrum antibiotic drug, ZOLYD (fosfomycin injection), for treating complicated urinary tract infections (cUTI) and expects to fi le a new drug application for the product in mid-2018. Fosfomycin has a long history outside the U.S., but the company has recast the injectable to improve its pharmacokinetics and pharmacodynamics against acute infections in a hospital setting. ZOLYD has a unique mechanism of action and is targeted at GRAM-positive and GRAM-negative infections, including those caused by multidrug-resistant bacteria.